

RESEARCH ARTICLE

Open Access



Clinical characteristics of SARS-CoV-2 pneumonia diagnosed in a primary care practice in Madrid (Spain)

Marina Guisado-Clavero¹, Ana Herrero Gil¹, Marta Pérez Álvarez¹, Marta Castelo Jurado¹, Ana Herrera Marinas², Vanesa Aguilar Ruiz¹, Ileana Gefaell Iarrondo¹, Miguel Menéndez Orenga³ and Sara Ares-Blanco^{1*} 

Abstract

Background: Possible cases of SARS-CoV-2 infection were diagnosed in primary care in Madrid, some of these cases had pneumonia. Most of the SARS-CoV-2 pneumonia published data came from hospitalised patients. This study set out to describe clinical characteristics of patients with SARS-CoV-2 pneumonia diagnosed in primary care across age groups and type of pneumonia.

Methods: Observational retrospective study obtaining clinical data from the electronic health records of patients who were followed-up by SARS-CoV-2 possible infection in a primary care practice in Madrid. All the cases were collected by in-person or remote consultation during the 10th March to the 7th of April. Exposure: Diagnosis of SARS-CoV-2 pneumonia by chest X-ray ordered by the GP. Main outcomes and measures: Symptoms of SARS-CoV-2 pneumonia, physical examination and diagnostic tests as a blood test, nasopharyngeal swab results for RT-PCR (Reverse transcriptase-polymerase chain reaction) and chest X-ray results.

Results: The overall SARS-CoV-2 pneumonias collected were 172 (female 87 [50.6%], mean age 60.5 years standard deviation [SD] 17.0). Comorbidities were body mass index ≥ 25 kg/m² (90 [52.3%]), hypertension (83 [48.3%]), dyslipidaemia (68 [39.5%]) and diabetes (33 [19.2%]). The sample was stratified by age groups (< 50 years, 50–75 years and ≥ 75 years). Clinical manifestations at onset were fever (144 [83.7%]), cough (140 [81.4%]), dyspnoea (103 [59.9%]) and gastrointestinal disturbances (72 [41.9%]). Day 7.8 (SD:4.1) from clinical onset was the mean day of pneumonia diagnosis. Bilateral pneumonia was more prevalent than unilateral (126 [73.3%] and 46 [26.7%]). Patients with unilateral pneumonia were prone to higher pulse oximetry (96% vs 94%, $p < 0.001$). We found differences between unilateral and bilateral cases in C-reactive protein (29.6 vs 81.5 mg/L, $p < 0.001$), and lymphocytes (1400.0 vs 1000.0E3/ml, $p < 0.001$). Complications were registered: 42 (100%) of patients ≥ 75 years were admitted into hospital; pulmonary embolism was only present at bilateral pneumonia (7 patients [5.6%]) and death occurred in 1 patient with unilateral pneumonia (2.2%) vs 10 patients (7.9%) with bilateral pneumonia (p 0.170).

Conclusion: Clinical manifestations of SARS-CoV-2 pneumonia were fever, cough and dyspnoea; this was especially clear in the elderly. We described different characteristics between unilateral and bilateral pneumonia.

Keywords: COVID-19, SARS-CoV-2, Pneumonia, Primary Care

*Correspondence: sara.ares@salud.madrid.org

¹ Federica Montseny Primary Care Centre. Av. Albufera 285, 28035 Madrid, Spain

Full list of author information is available at the end of the article



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background

The infection by the novel coronavirus SARS-CoV-2 is known as COVID-19 [1]. The World Health Organization declared the SARS-CoV-2 infection a pandemic on March 11th, 2020. Two days later, the Spanish government announced community transmission in the country and declared a national lockdown [2–4].

The incubation period of SARS-CoV-2 can vary from 2 to 14 days [5]. Almost 80% of infected people had mild symptoms or were asymptomatic, and 20% presented with severe symptoms which required hospital assistance [6]. Mild SARS-CoV-2 disease did not require hospital admissions, but these cases could transmit the virus [7]. The most commonly reported symptoms were fever, dry cough and dyspnoea, but it could be suspected if a patient referred digestive symptoms as diarrhoea or nausea, cutaneous exanthema or even neurosensory symptoms as headache, anosmia or ageusia [5, 8, 9]. Severe symptoms developed between day 7 and day 9 from the clinical onset with typical symptoms like fever, dyspnoea and pneumonia in the chest X-ray [9].

Spain reported 250,273 total cases till the 21st of May, confirmed by detection of viral RNA via reverse transcription-polymerase chain reaction (RT-PCR), of which 53.8% developed SARS-

CoV-2 pneumonia and 6.8% acute respiratory distress syndrome [10].

Other SARS-CoV-2 infection features were the dissociation between physical examination and chest X-ray findings described in hospital data [11]. Also, the most common laboratory characteristics in SARS-CoV-2 cases were high C-reactive protein (CRP) (58.3%, 95% confidence interval (CI) 21.8–94.7%), lymphopenia (43.1%, 95%CI 18.9–67.3) [12], increased fibrinogen and D-dimer [9, 13]. These last parameters had been suggested as risk factors for worst outcomes in SARS-CoV-2 infection; related to thromboembolism [14, 15]. Finally, some comorbidities had been reported as risk factors for poor prognosis like hypertension, diabetes, obesity, cardiovascular and respiratory chronic diseases [13, 16, 17].

In the European Surveillance System, Spain has been on the top three of most COVID-19 official cases reported [18]. Variations throughout countries could be related to differences in health care systems. Strong primary health care not only has been associated with better health outcomes in chronic diseases [19] but with offering patient-centred care [20]. In Spain, primary care has been key to detect presymptomatic and symptomatic cases. In the Madrid region, early detection of close contacts from infected cases and mild cases were followed by their primary care practice (PCP) from the outbreak onset. Despite the role of PCP to control the SARS-CoV-2 outbreak in the community, the literature about outpatient

SARS-CoV-2 cases is scarce in primary care. As GPs we wanted to know when SARS-CoV-2 pneumonia appeared and which symptoms and signs could help us to identify it earlier. Thus, the study aimed to describe the characteristics of patients who were diagnosed of pneumonia associated with SARS-CoV-2 in a PCP in Madrid (Spain) and to compare differences across the ages as well as between unilateral versus bilateral pneumonia presentations.


Methods

Study design

A retrospective observational study was conducted at Federica Montseny PCP at Madrid. This PCP is responsible to attend 21,814 people, 172 patients were included in this study (Fig. 1). The information was obtained from the electronic health record (EHR). The pneumonia cases due to SARS-CoV-2 infection were collected from those patients classified as possible cases who were examined by the PCP from the 10th of March to the 7th of April of 2020. Patients were eligible for the study if they were over 14 years old and the SARS-CoV-2 pneumonia was diagnosed by their general practitioner (GP) at PCP. We excluded patients whose diagnosis was made directly at the hospital without PCP intervention and those who did not belong to Federica Montseny PCP.

SARS-CoV-2 protocol in Madrid region

Patients were encouraged to phone their PCP and stay at home until their GP phoned them on the same day. In mild cases, patients received followed-up appointments at home by remote assessment using daily phone calls. In the case their symptoms worsened, they were advised to come to the PCP for examination where GPs would recommend taking a chest X-ray to rule out pneumonia. The criteria for requiring a chest X-ray were any COVID-19 progression symptom: persistent cough, thoracic pain, dyspnoea, persistent corporal temperature ($T > 37.3^\circ$) or physical abnormalities (tachypnoea, pulse oximetry $\leq 93\%$, abnormal lung auscultation). The X-ray department was in the same building than our practice. If pneumonia was diagnosed, the patient was referred to Accident and Emergency department (A&E) for laboratory tests and treatment. Mild pneumonia cases were followed-up by the PCP in conjunction with A&E team. Mild pneumonia was defined mainly as unilateral pneumonia as well as some cases of bilateral pneumonia with local patchy opacities; these patients did not have comorbidities; they were stable with good oximetry and without bad prognosis signs in their laboratory findings. The severe cases were referred straight to the A&E by their GPs. RT-PCR was not accessible at primary care so



patients were referred to A&E department at the diagnosis to be tested, some of the patients were admitted in hospitals where we could not check the RT-PCR result.

Variables

The main result was the type of pneumonia: unilateral or bilateral defined by chest X-ray results. Other variables were sociodemographic, comorbidities, prescribed chronic drugs, clinical characteristics of SARS-CoV-2 infection and laboratory results.

Statistical analysis

Descriptive analyses were carried out for demographic, personal background, physical examination and diagnostic tests, treatment and consequences of SARS-CoV-2 infection. Quantitative variables were expressed as means with standard deviation (SD) or by medians with interquartile range (IRQ), qualitative variables were expressed as percentages. Differences were evaluated using Chi-square test for categorical variables, T-test or ANOVA for normally

distributed variables and Wilcoxon–Mann–Whitney or Kruskal–Wallis test for non-normal variables. For all the statistical analyses, p -value (p) < 0.05 was considered significant. Data were stratified by age group (< 50 years, 50–75 years, \geq 75 years) and pneumonia unilateral or bilateral. All data were anonymised following national and international laws. All analyses were performed using STATA 16 and R 3.4.4.

Results

The PCP diagnosed and followed-up 1,023 patients with clinical symptoms of SARS-CoV-2 infection, SARS-CoV-2 pneumonia was present in 172 of those patients (Fig. 1). As shown in Table 1, 87 (50.6%) of the patients were female. The mean age of these 172 patients was 60.5 years. The most frequent comorbidities were body mass index \geq 25 kg/m² (BMI) (90 patients [52.3%]), hypertension (83 patients [48.3%]), dyslipidaemia (68 patients [39.5%]) and type 2 diabetes (33 patients [19.2%]). As expected, comorbidities increased with the patient's age; being those \geq 75 years who had a higher burden of disease. The prevalence of pulmonary thromboembolism was 4.1% (7 patients) without differences across the age distribution or sex, however, death was related to age (2 patients [2%] in 50–75 years old vs 9 patients [21%] of \geq 75 years and no deaths < 50 years, p < 0.001).

Clinical manifestations

Fever (144 patients [83.7%]) and cough (140 patients [81.4%]) were the most prevalent symptoms followed by dyspnoea (103 patients [59.9%]) and gastrointestinal disturbances (72 patients [41.9%]). We did not only describe the evolution of the symptoms during the infection till the onset of pneumonia (Fig. 2) but also across the different age groups (Fig. 3); we found myalgia and asthenia also common symptoms in the evolution. A box plot of pneumonia is represented on the bottom of Fig. 2, locating the median diagnosed day in the day 7 of clinical onset and the 50% of the sample from the day 5 to day 10.

We found clinical differences in the pneumonia syndrome among the different ages; not only did \geq 75 years have 1–3 symptoms (36 patients [86.0%]) more than < 50 years (20 patients [42.0%]) (p < 0.001) but their pneumonia onset was earlier, with a mean day 6.7 (SD 3.7) than the other groups (day 8.1 (SD 4.7) in < 50 years and day 8.3 (SD 3.8) in 50–75 years respectively). The group of < 50 years described \geq 4 symptoms in 28 patients (58.0%) compared to the other groups (40 patients [49.0%] in 50–75 years and 6 patients [14.0%] in \geq 75 years) (p < 0.001). The full description of the patients who did not survive can be checked in Additional file 1.

Physical examination and laboratory tests

The physical examination was not completed in all the cases; pulse oximetry was recorded in 162 patients (94.1%), heart rate in 138 patients (80.2%), the temperature in 131 patients (76.1%), lung auscultation in 92 patients (53.4%) and respiratory rate in 60 patients (34.8%). Basal pulse oximetry had a median value of 94.0% (IQR 92.0, 96.5), the median temperature was 37.2°C (IQR 36.7, 37.8). Statistically significant differences in pulse oximetry across the different ages and also the survivors versus no survivors were found. Patients \geq 75 years had the lowest values (92.0%) compared to < 50 years (96.0%) and 50–75 years (94.0%, p < 0.001) (Table 1). We also found differences comparing non-survivors with survivors (91.0% vs 94.0%) (Additional file 1). The pulse oximetry was \geq 94% in 98 patients (57.0%) of the whole population, that was achieved by 37 patients (77.0%) of < 50 years group, 48 patients (59.0%) of 50–75 years but only 13 patients (31.0%) of \geq 75 years group. We did not find differences in the auscultation, respiratory rate or temperature in the different ages.

Regarding the laboratory test, we did not find differences in the values except in lymphocytes. The median value for lymphocytes was 1100.0E3/ml, (IQR 800.0, 1500.0). The values were decreasing with age from 1250E3/ml (IQR 1000.0, 1750.0) in < 50 years, 1000.0 (IQR 800.0, 1400.0) in 50–75 years to 900E3/ml (600.0, 1200.0) in the \geq 75 years group (p 0.002).

Nasopharyngeal swab was obtained to confirm SARS-CoV-2 infection in 91.8% of patients (n:158) and it was positive in 70.9% of patients. A negative result was more frequent in < 50 years with 17 patients (35%) compared to \geq 75 years group with 6 patients (14%) as well as a positive result was more common in patients \geq 75 years group with 31 patients (74%) compared to those < 50 years with 27 patients (56%) (p 0.041).

Unilateral versus bilateral pneumonia

Unilateral pneumonia was present at 46 patients (26.7% [95% CI 20.3%-33.4%]) of the cases while bilateral pneumonia was found on 126 patients (73.3% [95%CI 66.9%-79.9%]) of the sample. We observed differences between the mean age in patients with unilateral versus bilateral pneumonia (53.7 vs 63.0 years) (Table 2). Patients with bilateral pneumonia had more comorbidities, however we only found statistical significance in hypertension (16 patients [34.8%] in unilateral pneumonia vs 67 patients [53.2%] in bilateral pneumonia, p 0.033), type 2 diabetes (4 patients [8.7%] in unilateral pneumonia vs 29 patients [23.0%] in bilateral pneumonia, p 0.035) or chronic kidney disease (no patients in unilateral pneumonia vs 12 patients [9.5%] in bilateral pneumonia, p 0.030). Patients with unilateral

Table 1 Clinical characteristics of SARS-CoV-2 pneumonia stratified by age groups

Age groups:	All	< 50 years	50–75 years	≥ 75 years	p value
Total number, n (%)	172 (100)	48 (27.9)	82 (47.7)	42 (24.4)	
Sociodemographic variables					
Age, mean (SD), years	60.5 (17.0)	39.0 (8.3)	62.1 (6.5)	81.9 (5.5)	< 0.001
Sex, n (%)					
Female	87 (50.6)	25 (52.0)	32 (39)	30 (71)	0.003
Male	85 (49.4)	23 (48.0)	50 (61)	12 (29)	
Comorbidities					
Cardiovascular risk factor					
Smoke habit, n (%)	13 (7.6)	3 (6)	10 (12)	0 (0)	0.062
BMI ≥ 25 kg/m ² , n (%)	90 (52.3)	16 (33)	51 (62)	23 (55)	0.012
Hypertension, n (%)	83 (48.3)	6 (12)	39 (48)	38 (90)	< 0.001
type 2 Diabetes, n (%)	33 (19.2)	0 (0)	21 (26)	12 (29)	< 0.001
Dyslipidemia, n (%)	68 (39.5)	11 (23)	32 (39)	25 (60)	0.002
Respiratory diseases					
Asthma, n (%)	21 (12.2)	4 (8)	7 (9)	10 (24)	0.031
COPD, n (%)	9 (5.2)	1 (2)	5 (6)	3 (7)	0.50
Cardiovascular diseases					
Ischaemic heart diseases, n (%)	9 (5.2)	0 (0)	3 (4)	6 (14)	0.007
Arrhythmias, n (%)	10 (5.8)	1 (2)	2 (2)	7 (17)	0.003
Heart failure, n (%)	7 (4.1)	0 (0)	3 (4)	4 (10)	0.072
Other diseases					
Chronic kidney diseases, n (%)	12 (7.0)	0 (0)	3 (4)	9 (21)	< 0.001
Cognitive impairment, n (%)	10 (5.8)	1 (2)	1 (1)	8 (19)	< 0.001
Cancer, n (%)	10 (5.8)	0 (0)	4 (5)	6 (14)	0.014
Rheumatological diseases, n (%)	14 (8.1)	3 (6)	6 (7)	5 (12)	0.58
Chronic treatment					
no drugs, n (%)	33 (19.2)	19 (40)	14 (17)	0 (0)	< 0.001
1–4 drugs, n (%)	68 (39.5)	25 (52)	35 (43)	8 (19)	
5–9 drugs, n (%)	43 (25.0)	3 (6)	20 (24)	20 (48)	
≥ 10 drugs, n (%)	28 (16.3)	1 (2)	13 (16)	14 (33)	
Antithrombotic/anticoagulant treat					
Antithrombotic drug, n (%)	14 (8.1)	1 (2)	7 (9)	6 (14)	0.019
Anticoagulant drug, n (%)	8 (4.7)	1 (2)	2 (2)	5 (12)	
Non consumption, n (%)	150 (87.2)	46 (96)	73 (89)	31 (74)	
Symptoms					
Fever, n (%)	144 (83.7)	41 (85)	74 (90)	29 (69)	0.003
Cough, n (%)	140 (81.4)	43 (90)	68 (83)	29 (69)	0.039
Dyspnea, n (%)	103 (59.9)	29 (60)	50 (61)	24 (57)	0.91
Gastrointestinal disturbances, n(%)	72 (41.9)	23 (48)	32 (39)	17 (40)	0.60
Myalgias, n (%)	51 (29.7)	15 (31)	30 (37)	6 (14)	0.035
Thoracic Pain, n (%)	27 (15.7)	17 (35)	9 (11)	1 (2)	< 0.001
Pleural chest Pain, n (%)	10 (5.8)	4 (8)	6 (7)	0 (0)	0.17
Rhinitis, n (%)	8 (4.7)	4 (8)	4 (5)	0 (0)	0.17
Odynophagia, n (%)	20 (11.6)	8 (17)	8 (10)	4 (10)	0.44
Asthenia, n (%)	47 (27.3)	13 (27)	20 (24)	14 (33)	0.57
Headache, n (%)	47 (27.3)	13 (27)	20 (24)	14 (33)	0.57
Dysgeusia, n (%)	9 (5.2)	6 (12)	3 (4)	0 (0)	0.020
Anosmia, n (%)	2 (1.2)	1 (2)	1 (1)	0 (0)	0.65

Table 1 (continued)

Age groups:	All	< 50 years	50–75 years	≥ 75 years	p value
Symptoms categorized					
1–3 total symptoms, n (%)	97 (56.7)	20 (42)	41 (51)	36 (86)	< 0.001
≥ 4 total symptoms, n (%)	74 (43.3)	28 (58)	40 (49)	6 (14)	
Physical examination					
Temperature, median (IQR), °C	37.2 (36.7, 37.8)	37.3 (0.8)	37.4 (0.8)	37.0 (0.8)	0.060
Heart rate, mean (SD), bpm	93.2 (16.1)	99.6 (13.8)	93.3 (16.5)	85.9 (15.1)	< 0.001
Respiratory rate, (median (IQR), rpm	16.0 (15.0, 21.0)	16.0 (15.0, 16.0)	18.0 (15.5, 21.0)	22.0 (15.0, 25.0)	0.028
Pulse oximetry, median (IQR), %	94.0 (92.0, 96.5)	96.0 (94.0, 97.5)	94.0 (92.0, 96.0)	92.0 (88.5, 94.0)	< 0.001
Normal lung auscultation, n (%)	38 (22.1)	13 (27)	21 (26)	4 (10)	0.16
Abnormal lung auscultation, n (%)	54 (31.4)	12 (25)	24 (29)	18 (43)	0.16
Blood test					
CRP, median (IQR), mg/L	65.3 (29.0, 128.0)	57.0 (12.8, 115.0)	60.9 (34.0, 135.0)	81.5 (45.0, 133.0)	0.32
Lymphocytes, median (IQR), 10e3/ml	1100.0 (800.0, 1500.0)	1250.0 (1000.0, 1750.0)	1000.0 (800.0, 1400.0)	900.0 (600.0, 1200.0)	0.002
D-Dimer, median (IQR), µg/L	445.0 (288.0, 910.0)	410.0 (240.0, 901.5)	460.0 (270.0, 880.0)	464.0 (320.0, 2160.0)	0.39
Fibrinogen ≥ 500, n (%), mg/dL	127 (73.8)	31 (65)	62 (76)	34 (81)	0.29
Ferritin, median (IQR), µg/L	443.5 (200.0, 1215.0)	474.0 (320.0, 1738.0)	494.0 (203.0, 913.0)	325.5 (184.5, 1006.5)	0.73
RT-PCR SARS-CoV-2					
Negative, n (%)	36 (20.9)	17 (35)	13 (16)	6 (14)	0.041
Positive, n (%)	122 (70.9)	27 (56)	64 (78)	31 (74)	0.042
Pneumonia features					
Pneumonia onset, mean (SD), days	7.8 (4.1)	8.1 (4.7)	8.3 (3.8)	6.7 (3.7)	0.12
Unilateral, n (%)	46 (26.7)	21 (44)	19 (23)	6 (14)	0.003
Bilateral, n (%)	126 (73.3)	27 (56)	63 (77)	36 (86)	0.004
Complications					
Hospital admission, n (%)	140 (81.4)	30 (62)	68 (83)	42 (100)	< 0.001
Pulmonary thromboembolism, n (%)	7 (4.1)	2 (4)	2 (2)	3 (7)	0.45
Death, n (%)	11 (6.4)	0 (0)	2 (2)	9 (21)	< 0.001

n number, SD standard deviation, BMI body mass index, COPD chronic obstructive pulmonary disease, IQR interquartile range, CRP C-reactive protein, RT-PCR reverse transcription PCR, bpm beats per minute, rpm respiratory rate per minute


pneumonia presented more frequently myalgia (17 patients [37.0%]) and chest pain (10 patients [21.7%]). Bilateral pneumonia had more dyspnoea (79 patients [62.7%]), but no significant differences were found in clinical characteristics. On the one hand, patients with unilateral pneumonia were prone to normal auscultation compared to bilateral cases (16 patients [34.8%] vs 22 patients [17.5%], p 0.014) and higher pulse oximetry (96% vs 94%, p < 0.001). We found statistical significance between unilateral and bilateral cases in CRP (29.6 vs 81.5 mg/L), lymphocytes (1400.0 vs 1000.0E3/ml) and fibrinogen ≥ 500 mg/dL (24 patients [52.2%] vs 103 [81.7%]). Unilateral pneumonia had more negative RT-PCR, 17 patients (37.0%) vs 19 patients (15.1%) of bilateral ones (p 0.006). 20 patients (43.5%) with unilateral pneumonia required hospital admission in comparison to 120 patients (95.2%) of bilateral pneumonia however pulmonary embolism was only present at bilateral pneumonia (7 patients [5.6%]). Death was

present chiefly on bilateral cases (1 patient in unilateral cases [2.2%] vs 10 patients [7.9%], p 0.170) (Table 2).

Discussion

In this study, females were 50.3% of the population. The age distribution was asymmetric, however non-survivors belonged mainly to the elderly. The most prevalent comorbidities were hypertension, dyslipidaemia and BMI ≥ 25Kg/m². Clinical manifestations of SARS-CoV-2 pneumonia were fever and cough as the main symptoms, most of the patients had only 1–3 symptoms; this was especially clear in the elderly (≥ 75 years) whose clinical presentation was mainly with 1–3 symptoms. We described different characteristics between unilateral and bilateral pneumonia.

Some publications have been reporting age as a factor for developing severe illness due to SARS-CoV-2 infection [13], our study is consistent with this observation because elderly patients had more frequently bilateral



pneumonia and also morbidity compared to younger patients. These findings are in concordance to Liu et al. who found more bilateral pneumonia in older patients [21]. However, elderly presented fewer symptoms than those younger than 75 years because they used to have less pneumonia symptoms [22] and also their own comorbidities could overlap some COVID-19 symptoms. The comorbidities of our population (hypertension, dyslipidemia, diabetes and $BMI \geq 25 \text{Kg/m}^2$) were similar to the studies that have been published [13, 17]. These

results are consistent with a meta-analysis published by Yang et al. [16], they found that patients infected by SARS-CoV-2 had hypertension (21.1%) and diabetes (9.7%) as the most prevalent comorbidities. Smoking was present in 7.5% of our population, less than others. Guan et al. [6] reported 12.6% in smokers, that difference could be explained by incomplete EHR.

In this study, we described the symptoms and their chronology up until the appearance of pneumonia. We were interested in describing clinical patterns that




Table 2 Differences between SARS-CoV-2 pneumonia patterns: unilateral and bilateral

Pneumonia	Unilateral	Bilateral	p-value
Number (%)	46 (26.7)	126 (73.3)	
Pneumonia onset, mean (SD), days	8.2 (5.1)	7.7 (3.7)	0.47
Sociodemographic variables			
Age, mean (SD), years	53.7 (16.6)	63.0 (16.6)	
Sex, n (%)			
Female	28 (60.9)	59 (46.8)	0.10
Male	18 (39.1)	67 (53.2)	0.10
Comorbidities			
Cardiovascular risk factor			
Smoke habit, n (%)	4 (8.7)	9 (7.1)	0.38
BMI \geq 25 kg/m ² , n (%)	20 (43.5)	70 (55.6)	0.25
Hypertension, n (%)	16 (34.8)	67 (53.2)	0.033
type 2 Diabetes, n (%)	4 (8.7)	29 (23.0)	0.035
Dyslipidemia, n (%)	15 (32.6)	53 (42.1)	0.26
Respiratory diseases			
Asthma, n (%)	4 (8.7)	17 (13.5)	0.40
COPD, n (%)	3 (6.5)	6 (4.8)	0.65
Cardiovascular diseases			
Ischaemic heart diseases, n (%)	1 (2.2)	8 (6.3)	0.28
Arrhythmias, n (%)	1 (2.2)	9 (7.1)	0.22
Heart failure, n (%)	2 (4.3)	5 (4.0)	0.91
Other diseases			
Chronic kidney diseases, n (%)	0 (0.0)	12 (9.5)	0.030
Cognitive impairment, n (%)	3 (6.5)	7 (5.6)	0.81
Cancer, n (%)	1 (2.2)	9 (7.1)	0.22
Rheumatological diseases, n (%)	2 (4.3)	12 (9.5)	0.27
Chronic treatment			
no drugs, n (%)	8 (17.4)	25 (19.8)	0.60
1–4 drugs, n (%)	21 (45.7)	47 (37.3)	
5–9 drugs, n (%)	12 (26.1)	31 (24.6)	
\geq 10 drugs, n (%)	5 (10.9)	23 (18.3)	
Antithrombotic/anticoagulant treatment			
Antithrombotic drug, n (%)	1 (2.2)	13 (10.3)	0.22
Anticoagulant drug, n (%)	2 (4.3)	6 (4.8)	
Non consumption, n (%)	43 (93.5)	107 (84.9)	
Symptoms			
Fever, n (%)	38 (82.6)	106 (84.1)	0.81
Cough, n (%)	37 (80.4)	103 (81.7)	0.84
Dyspnea, n (%)	24 (52.2)	79 (62.7)	0.21
Gastrointestinal disturbances, n(%)	18 (39.1)	54(42.9)	0.66
Myalgias, n (%)	17 (37.0)	34 (27.0)	0.20
Thoracic Pain, n (%)	10 (21.7)	17 (13.5)	0.19
Pleural chest Pain, n (%)	6 (13.0)	4 (3.2)	0.014
Rhinitis, n (%)	4 (8.7)	4 (3.2)	0.13
Odynophagia, n (%)	7 (15.2)	13 (10.3)	0.37
Asthenia, n (%)	12 (26.1)	35 (27.8)	0.83
Headache, n (%)	12 (26.1)	35 (27.8)	0.83
Dysgeusia, n (%)	3 (6.5)	6 (4.8)	0.65
Anosmia, n (%)	1 (2.2)	1 (0.8)	0.45

Table 2 (continued)

Pneumonia	Unilateral	Bilateral	p-value
Symptoms categorized			
1–3 total symptoms, n (%)	25 (54.3)	72 (57.6)	0.70
≥ 4 total symptoms, n (%)	21 (45.7)	53 (42.4)	
Physical examination			
Temperature, mean (SD), °C	37.2 (0.8)	37.3 (0.8)	0.86
Heart rate, mean (SD), bpm	96.2 (15.1)	92.2 (16.4)	0.20
Respiratory rate, median (IQR), rpm	16.0 (14.0, 16.0)	17.0 (15.0, 22.0)	0.073
Pulse oximetry, median (IQR), %	96.0 (94.0, 97.0)	94.0 (91.0, 96.0)	< 0.001
Normal lung auscultation, n (%)	16 (34.8)	22 (17.5)	0.014
Abnormal lung auscultation, n (%)	8 (17.4)	46 (36.5)	0.014
Blood test			
CRP, median (IQR), mg/L	29.6 (5.0, 81.5)	81.5 (46.2, 143.0)	< 0.001
Lymphocytes, median (IQR), 10e3/ml	1400.0 (1100.0, 1880.0)	1000.0 (800.0, 1400.0)	< 0.001
D-Dimer, median (IQR), µg/L	339.0 (197.0, 464.0)	520.0 (320.0, 1030.0)	0.035
Fibrinogen ≥ 500, n (%), mg/dL	24 (52.2)	103 (81.7)	< 0.001
Ferritin, median (IQR), µg/L	618.0 (280.5, 919.0)	424.0 (200.0, 1215.0)	0.96
RT-PCR SARS-CoV-2			
Negative, n (%)	17 (37.0)	19 (15.1)	0.006
Positive, n (%)	25 (54.3)	97 (77.0)	
Complications			
Hospital admission, n (%)	20 (43.5)	120 (95.2)	< 0.001
Pulmonary thromboembolism, n (%)	0 (0.0)	7 (5.6)	0.10
Death, n (%)	1 (2.2)	10 (7.9)	0.17

n number, SD standard deviation, BMI body mass index, COPD chronic obstructive pulmonary disease, IQR interquartile range, CRP C-reactive protein, RT-PCR reverse transcription PCR, bpm beats per minute, rpm respiratory rate per minute

could help us to decide when to request a chest X-ray and how to detect pneumonia. As expected, we found fever (83.8%), cough (81.5%), dyspnea (59.5%) and myalgia (30.1%) as the most frequent symptoms, consistent with the literature [9, 12] and with Sun et al. [23] who reported fever (89.1%) and cough (72.2%) as the most frequent symptoms; the differences among their percentages and ours could be explained by the accuracy in the EHR because the record was made daily.

We collected 12 symptoms, fever, cough and dyspnea were the most frequent, consistent with the meta-analysis of Rodriguez et al. who reported fever (88.7%, 95% CI 84.5–92.9%), cough (57.6%, 95%CI 40.8–74.4%) and dyspnea (45.6%, 95% CI 10.9–80.4%). We observed that most of the patients exhibited only 1–3 symptoms (56.1%). In our study the elderly had fewer symptoms, which is consistent with Niu et al. [24] who described less dyspnoea and cough in patients over 80 years however in their study fever ($\geq 37.3^\circ\text{C}$) was more prevalent than in our study (75% vs 69%); maybe this could be explained by the different age ranges (in their case: 50–64, 65–79 and ≥ 80 years).

In this study, the diagnosis of pneumonia was on day 7.8 of onset of the symptoms, similar to Wang et al. [25]

where at hospital admission had a median on day 7.0 (IQR 4.0, 8.0). These periods were longer than other publications which established the diagnosis through day 3.0 (IQR 1.0, 6.0) for non-severe SARS-CoV-2 infection but on day 5.0 (IQR 2.0, 7.0) in severe infections [6]. Our study found that the diagnosis in the elderly group was made on day 6.7 of the onset. Furthermore, this group had more deaths (21%) and they were the ones who suffered more severe disease. They had tachypnoea, 92% of pulse oximetry, 43% of abnormal auscultation as well as more abnormalities in their blood tests. Most manuscripts published did not compare the differences across age groups because they were focused on severe and not severe cases. Niu et al. described 90.6% of oximetry and death in 18.8 of their ≥ 80 years patients which is similar to our results.

On another note, the physical examination was not recorded in all patients. At the moment, we still do not know the predictive values of symptoms and physical examination in COVID-19, especially of the lung auscultation which involves physical touch. In Spain, we suffered a shortage of personal protective equipment (PPE) for healthcare workers (40,921 of healthcare workers were infected by SARS-CoV-2 in the country till 11th of

May [10] which made doctors cautious of examining the patients if they could get a diagnosis through anamnesis and chest X-ray. If we compare with other series, Guan et al. do not detail these physical signs in their data as well as Zhou et al. who just describe respiratory rate in 29% of their patients [26]. A survey [27] was conducted in Canada to explore the opinions of GPs during the SARS (2003) and H1N1 (2010) outbreaks, GPs answered that they would avoid physical examinations in patients with SARS (62%) and patients with H1N1 (18%). More studies should be conducted to observe the benefit of the physical examination in the management of COVID-19. This should come along with qualitative research to understand the perspective of the doctors.

We described two clinical patterns by chest X-ray: unilateral and bilateral pneumonia however, little is known about other differences between both types of pneumonia [12]. In this study, 73.3% of the types of pneumonia were bilateral; our results are in concordance with Shi et al. (n:416) [28] and Chen et al. [29], where around 75% of cases of pneumonia corresponded to bilateral and 25% to unilateral. Shi et al. as well as Guan et al. described bilateral pneumonia more frequently in severe cases. Unilateral pneumonia appeared more frequently in younger patients (53.7 vs 62.8 years), the onset was slightly later than bilateral pneumonia (8.9 vs 7.8 days) and most of them did not have red flags on their examination (abnormal auscultation, oximetry $\leq 94\%$) or blood tests (CRP ≥ 81.5 mg/L, D-Dimer ≥ 520 $\mu\text{g/L}$, Lymphocytes $\leq 1,000$ $10^3/\text{L}$, Fibrinogen ≥ 500 mg/dL) [6, 28]. They had higher oximetry (96% vs 94%) and more normal auscultation (34.8% vs 17.5%) without differences in other physical signs or symptoms. Unilateral pneumonia presented 37% of negative RT-PCR similar to Weissleder et al. who reported 30% (range:10–40%) of false negative results [30]. Any of our patients with unilateral pneumonia had a pulmonary embolism and just one of them did not survive.

Finally, health systems have faced significant stress because of pandemic, unfortunately more pandemic waves could happen till vaccination is available. This situation has highlighted the need for a whole patient perspective to take decisions especially when patients are assessed by remote consultation. Priority should be given to primary care who have a long-term relationship with their patients because not only they can follow them but they can manage those SARS-CoV-2 pneumonia patients without red flags in settings with access to laboratory tests and chest X-ray. We have found that unilateral pneumonia without red flags could be monitored closely in primary care without referring patients to the hospital if they can assure follow-up tightly. We hypothesise that unilateral SARS-CoV-2 pneumonia

without red flags could be managed in primary care but more research is needed to characterise these clinical patterns related to the age and unilateral vs bilateral pneumonia.

Strengths and limitations

To our knowledge, our study is the first one to describe patients with SARS-CoV-2 pneumonia diagnosed in a PCP. Besides, we described the clinical differences between bilateral and unilateral cases of pneumonia. However, limitations of this observational study should be addressed. Firstly, this study was carried out in a unique PCP, so the results might not be widely generalisable. The cardiovascular factors could not be updated in the EHR (especially tobacco or BMI) but the comorbidities are usually updated because we have validated the diagnosis for research with success in other studies [31]. In addition, a bias should be considered because we are located in a primary health centre which include a radiology department, so that we had facilities to diagnose SARS-CoV-2 pneumonia compared to other primary health centers of Madrid. Our study described the symptoms up through the onset of pneumonia but some of unilateral pneumonia should be addressed more thoroughly. On the one hand, we have not collected whether or not they could progress to bilateral pneumonia. On the other hand, we should approach differently those unilateral pneumonia with negative RT-PCR; we should have evidence if the RT-PCR was repeated several times. Further studies should be conducted to clarify these cases. Finally, we based our pneumonia diagnosis in the radiologist description but there could be an interpersonal variability in that description.

Conclusions

SARS-CoV-2 pneumonia had mainly fever, cough and dyspnoea symptoms, particularly in the elderly. We found two clinical patterns: unilateral and bilateral pneumonia. Unilateral pneumonia appeared more frequently in younger patients without red flags in their physical examination or laboratory tests however bilateral pneumonia was more common in elderly patients with red flags. Primary care can manage mild pneumonia through anamnesis and proper diagnostic tests.

Abbreviations

A&E: Accident and Emergency department; BMI: Body mass index; CI: Confidence interval; CRP: C-reactive protein; EHR: Electronic health record; GP: General practitioner; IRQ: Interquartile range; *p*: *P* Value; PCP: Primary care practice; RT-PCR: Reverse transcriptase-polymerase chain reaction; SD: Standard deviation.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12875-021-01430-y>.

Additional file 1. Clinical characteristics between survivors and non-survivors SARS-CoV-2 pneumonia patients.

Acknowledgements

We would like to thank all the healthcare professionals who worked tirelessly during the SARS-CoV-2 pandemic in the Madrid region. We are especially grateful for the support of those working at Federica Montseny PHCC and University Hospital Infanta Leonor. L. Flippin, S. Collen and E. García provided professional writing services. We would like to thank E. Polentinos and L. Castelo for guidance in the revision of the manuscript.

Authors' contributions

SAB, MGC and MM had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. *Study concept and design* SAB and MM. *Acquisition, analysis, or interpretation of data:* SAB, MGC, AHG, MPA, MCJ, AHM, VAR, IGI and MM. *Drafting of the manuscript:* MGC, SAB. *Critical revision of the manuscript for important intellectual content:* SAB, MM, EP and LC. *Statistical analysis:* SAB, MM. *Administrative, technical, or material support:* SAB, MGC, AHG, MPA, MCJ, AHV, VAR, IGI and MM. *Supervision:* MGC, SAB. All Authors read and approved the manuscript.

Funding

This study was funded by the Fundación para la investigación e innovación biosanitaria en Atención Primaria (FIIBAP). The funder had no role in study design or in the decision to submit the report for publication.

Availability of data and materials

The datasets generated and/or analysed during the current study are not publicly available to protect participant privacy, but are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

This study was approved by the Ethics Committee of University Hospital Gregorio Marañón (13/2020), the Primary Care Southeast Research Committee (CLISE) at Madrid region (09/20) and the Spanish Drug Agency (AEMPS). No written informed consent was obtained for children as all participants were over 18 years old. The Ethics Committee of University Hospital Gregorio Marañón has waived the requirement of the informed consent for this study.

Consent for publication

Not applicable.

Competing interests

None declared.

Author details

¹Federica Montseny Primary Care Centre. Av. Albufera 285, 28035 Madrid, Spain. ²Accident and Emergency Department, Hospital Infanta Leonor, Av. Gran Vía del Este, 80, 28031 Madrid, Spain. ³Research Institute I+12 (CIBERESP), 12 de Octubre Hospital, Av. de Córdoba, s/n, 28041 Madrid, Spain.

Received: 8 July 2020 Accepted: 7 April 2021

Published online: 29 April 2021

References

- World Health Organization: Naming the coronavirus disease (COVID-19) and the virus that causes it. [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-\(covid-2019\)-and-the-virus-that-causes-it](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it). Accessed 27 May 2020.
- Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. *Lancet*. 2020;395(10223):470–3.
- World Health Organization: WHO Director-General's opening remarks at the media briefing on COVID-19. <https://www.who.int/dg/speeches/detail/who-directorgeneral-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020>. Accessed 27 May 2020.
- Gobierno de España: Boletín Oficial del Estado. https://www.boe.es/diario_boe/txt.php?id=BOE-A-2020-3692. Accessed 27 May 2020.
- Sohrabi C, Alsafi Z, O'Neill N, Khan M, Kerwan A, Al-Jabir A, et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). *Int J Surg [Internet]*. 2020;76:71–6. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S1743919120301977>.
- Guan W-J, Ni Z-Y, Hu YY-H, Liang W-H, Ou C-Q, He J-X, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020;28:1–13.
- Gandhi RT, Lynch JB, Del Rio C. Mild or Moderate Covid-19. *N Engl J Med [Internet]*. 2020;383(18):1757–66. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/32329974>.
- Diaz-Guimaraens B, Dominguez-Santas M, Suarez-Valle A, Pindado-Ortega C, Selda-Enriquez G, Bea-Ardebol S, et al. Petechial Skin Rash Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *JAMA Dermatol*. 2020;2017(C):1–3.
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan China. *Lancet*. 2020;395:497–506.
- Instituto Carlos III: Informes COVID-19 <https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Paginas/InformesCOVID-19.aspx>. Accessed 27 May 2020.
- Yang W, Cao Q, Qin L, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): A multi-centre study in Wenzhou city, Zhejiang China. *J Infect*. 2020;80(4):388–93.
- Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. *Travel Med Infect Dis*. 34:101623.
- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet (London, England)*. 2020;6736(20):1–9.
- Grillet F, Behr J, Calame P, Aubry S, Delabrousse E. Acute Pulmonary Embolism Associated with COVID-19 Pneumonia Detected by Pulmonary CT Angiography. *Radiology*. 2020;23:201544.
- Gao Y, Li T, Han M, Li X, Wu D, Xu Y, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. *J Med Virol [Internet]*. 2020;92(7):791–6. Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25770>.
- Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. *Int J Infect Dis*. 2020;94:91–5.
- Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA*. 2020;10022:1–8.
- ECDC. COVID Surveillance Report. 2020. <https://www.ecdc.europa.eu/en/covid-19/situation-updates>. Accessed 27 May 2020.
- Starfield B, Shi L, Macinko J. Contribution of primary care to health systems and health. *Milbank Q*. 2005;83(3):457–502.
- OECD. Realising the Potential of Primary Health Care. OECD; 2020. 1–16 p. (OECD Health Policy Studies). <http://www.oecd.org/health/health-systems/OECD-Policy-Brief-Primary-Health-Care-May-2019.pdf>. Accessed 27 May 2020.
- Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients. *J Infect*. 2020;80:e14–8.
- Fein AM. Pneumonia in the elderly: Special diagnostic and therapeutic considerations. *Med Clin North Am*. 1994;78(5):1015–33.
- Sun P, Qie S, Liu Z, Ren J, Li K, Xi J. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: A single arm meta-analysis. *J Med Virol*. 2020;92(6):612–7.
- Niu S, Tian S, Lou J, et al. Clinical characteristics of older patients infected with COVID-19: A descriptive study. *Arch GerontolGeriatr*. 2020;89:104058.

25. Wang D, Hu B, Hu C, Clinical Characteristics of 138 Hospitalized Patients with, et al. Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*. 2019;2020:1–9.
26. Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan China. *Ann Oncol*. 2020;31(7):894–901.
27. Jaakkimainen RL, Bondy SJ, Parkovnick M, Barnsley J. How infectious disease outbreaks affect community-based primary care physicians: comparing the SARS and H1N1 epidemics. *Can FamPhys*. 2014;60(10):917–25.
28. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan China. *JAMA Cardiol*. 2020;25:e200950.
29. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020;395(10223):507–13.
30. Weissleder R, Lee H, Ko J, Pittet MJ. COVID-19 diagnostics in context. *SciTransl Med*. 2020;12(546):1–7.
31. de Burgos-Lunar C, Salinero-Fort MA, Cárdenas-Valladolid J, et al. Validation of diabetes mellitus and hypertension diagnosis in computerized medical records in primary health care. *BMC Med Res Methodol*. 2011;11(1):146.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

